Advertisement
Mayo Clinic Proceedings Home

Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies

      Abstract

      Antiphospholipid (aPL) antibodies have historically been postulated to cause a poorly understood inflammatory myelitis. Neuromyelitis optica spectrum disorder (NMOSD) causes an inflammatory longitudinally extensive transverse myelitis (LETM). In 2004, aquaporin-4 immunoglobulin G (AQP4-IgG) was first reported as a highly specific (>99%) serum diagnostic biomarker of NMOSD, distinguishing it from other disorders (eg, multiple sclerosis). We sought to assess the frequency of AQP4-IgG (and thus NMOSD diagnosis) in LETM with aPL antibodies. We searched Mayo Clinic records (from January 1, 1996, through December 31, 2014) for patients with (1) LETM and (2) aPL or β2-glycoprotein I antibodies and (3) a serum sample available. AQP4-IgG was evaluated in the 24 included patients and in 20 controls with aPL antibodies but without myelitis. Seropositivity for AQP4-IgG was confirmed in 11 of 24 patients with LETM (46%), confirming an AQP4-IgG–seropositive NMOSD diagnosis rather than aPL-associated LETM. Six of 11 AQP4-IgG–seropositive patients (54%) were initially diagnosed as having aPL/lupus-associated myelitis. Recurrent LETM was exclusive to AQP4-IgG–seropositive patients (P=.003). Alternative diagnoses assigned to the remaining 13 AQP4-IgG–seronegative patients included idiopathic transverse myelitis (n=5), seronegative NMOSD (n=2), spinal cord infarct attributed to aPL antibodies (n=2), spinal cord sarcoidosis (n=1), varicella-zoster virus myelitis (n=1), postinfectious myelitis (n=1), and multiple sclerosis (n=1). All 20 controls were seronegative for AQP4-IgG. Clotting disorders occurred in 36% of patients (4 of 11) with LETM with both aPL antibodies and AQP4-IgG. AQP4-IgG should be tested in all patients with LETM and aPL antibodies because AQP4-IgG–seropositive NMOSD accounts for almost half of all cases. Clotting disorders are common in patients with LETM with dual positivity for AQP4-IgG and aPL antibodies.

      Abbreviations and Acronyms:

      Ab (antibody), aPL (antiphospholipid), APS (antiphospholipid syndrome), AQP4-IgG (aquaporin-4 immunoglobulin G), CNS (central nervous system), DVT (deep venous thrombosis), LETM (longitudinally extensive transverse myelitis), MRI (magnetic resonance imaging), NMOSD (neuromyelitis optica spectrum disorder), PE (pulmonary embolism), SLE (systemic lupus erythematosus), STIR (short tau inversion recovery)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • Lennon V.A.
        • Wingerchuk D.M.
        • Kryzer T.J.
        • et al.
        A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
        Lancet. 2004; 364: 2106-2112
        • Popescu B.F.
        • Lennon V.A.
        • Parisi J.E.
        • et al.
        Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.
        Neurology. 2011; 76: 1229-1237
        • Flanagan E.P.
        • Weinshenker B.G.
        • Krecke K.N.
        • et al.
        Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
        JAMA Neurol. 2015; 72: 81-87
        • Wingerchuk D.M.
        • Weinshenker B.G.
        The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease.
        Mult Scler. 2012; 18: 5-10
        • Hochberg M.C.
        Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
        Arthritis Rheum. 1997; 40: 1725
        • Tan E.M.
        • Cohen A.S.
        • Fries J.F.
        • et al.
        The 1982 revised criteria for the classification of systemic lupus erythematosus.
        Arthritis Rheum. 1982; 25: 1271-1277
        • Miyakis S.
        • Lockshin M.D.
        • Atsumi T.
        • et al.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J Thromb Haemost. 2006; 4: 295-306
        • Flanagan E.P.
        • McKeon A.
        • Weinshenker B.G.
        Anterior spinal artery infarction causing man-in-the-barrel syndrome.
        Neurol Clin Pract. 2014; 4: 268-269
        • Rodrigues C.E.
        • de Carvalho J.F.
        Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature.
        Semin Arthritis Rheum. 2011; 40: 349-357
        • Guerra H.
        • Pittock S.J.
        • Moder K.G.
        • Froehling D.A.
        • Flanagan E.P.
        Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis.
        J Neurol Sci. 2016; 361: 204-205
        • Waters P.J.
        • McKeon A.
        • Leite M.I.
        • et al.
        Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
        Neurology. 2012; 78 (discussion 669): 665-671
        • long Y.
        • He Y.
        • Zheng Y.
        • Chen M.
        • Zhang B.
        • Gao C.
        Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder.
        J Neurol. 2013; 260: 3150-3157
        • Pittock S.J.
        • Lennon V.A.
        • de Seze J.
        • et al.
        Neuromyelitis optica and non organ-specific autoimmunity.
        Arch Neurol. 2008; 65: 78-83
        • Kitley J.
        • Leite M.I.
        • Kuker W.
        • et al.
        Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
        JAMA Neurol. 2013; 70: 1375-1381
        • Jiao Y.
        • Fryer J.P.
        • Lennon V.A.
        • et al.
        Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.
        JAMA Neurol. 2014; 71: 48-54
        • Jurynczyk M.
        • Messina S.
        • Woodhall M.R.
        • et al.
        Clinical presentation and prognosis in MOG-antibody disease: a UK study.
        Brain. 2017; 140: 3128-3138
        • Foroughipour M.
        • Nikbin Z.
        • Sahebari M.
        • Pezeshki Rad M.
        • Shoeibi A.
        Devic syndrome: can antiphospholipid antibodies be a factor?.
        J Clin Rheumatol. 2012; 18: 419-421
      1. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum [published online February 17, 2016]. Ann Neurol. https://doi.org/10.1002/ana.24617.

        • Nour M.M.
        • Nakashima I.
        • Coutinho E.
        • et al.
        Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
        Neurology. 2016; 86: 79-87
        • Saadoun S.
        • Waters P.
        • Leite M.I.
        • Bennett J.L.
        • Vincent A.
        • Papadopoulos M.C.
        Neuromyelitis optica IgG causes placental inflammation and fetal death.
        J Immunol. 2013; 191: 2999-3005
        • Farber R.S.
        • Gross R.
        • Zakin E.
        • Fabian M.
        Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse.
        Mult Scler. 2017; 23: 988-994
        • Kleiter I.
        • Gahlen A.
        • Borisow N.
        • et al.
        Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses.
        Ann Neurol. 2016; 79: 206-216
        • Flanagan E.P.
        • Kaufmann T.J.
        • Krecke K.N.
        • et al.
        Discriminating long myelitis of neuromyelitis optica from sarcoidosis.
        Ann Neurol. 2016; 79: 437-447